Strain-level genetic heterogeneity and colonization dynamics drive microbiome therapeutic efficacy.

FMT improves anti-PD-1 efficacy and progression-free survival in a single-arm trial of advanced PD-L1-negative NSCLC patients.

• The trial was a single-arm study design focused on advanced NSCLC patients with PD-L1-negative status.
• FMT was combined with anti-PD-1 immunotherapy.
• Progression-free survival was a measured clinical endpoint showing improvement.
• The patient population represented a group previously considered unlikely to benefit from checkpoint inhibitor therapy alone due to PD-L1-negative status.

Phylogenetically distinct strains within identical species exert opposing therapeutic effects, resolving prior inconsistencies in the microbiome-immunotherapy literature.

• The analysis was conducted using a high-resolution strain-tracking framework.
• Over 2,000 metagenomes from diverse disease cohorts and healthy controls were analyzed.
• Strains classified under the same species name were found to have divergent and even opposing impacts on therapeutic outcomes.
• This strain-level heterogeneity is identified as the mechanistic basis for variable outcomes across prior studies.

Engraftment of transplanted microbiota relies on species-intrinsic metabolic and immune evasion traits, representing conserved ecological principles.

• Metabolic traits of the donor species were identified as determinants of successful colonization in the recipient.
• Immune evasion traits were also identified as species-intrinsic factors driving engraftment success.
• These principles were described as 'conserved ecological principles' applicable across cohorts.
• The findings were derived from analysis of over 2,000 metagenomes spanning diverse disease cohorts and healthy controls.

Successful colonization by specific beneficial strain variants correlates with positive clinical outcomes.

• The correlation was identified between engraftment of particular strain variants and favorable patient outcomes.
• The analysis distinguished between strain variants within the same species, showing differential clinical impact.
• This finding links the ecological engraftment dynamics directly to therapeutic efficacy at the strain level.
• The result supports a 'strain-function-efficacy paradigm' as described by the authors.

38 priority species were identified with robust engraftment potential and significant heterogeneity as candidates for precision therapeutics.

• Exactly 38 species were designated as priority candidates for next-generation microbiome drug development.
• Selection criteria included robust engraftment potential across cohorts.
• Significant intra-species heterogeneity was a defining characteristic of these 38 species.
• These species are proposed as the basis for precision microbiome therapeutics rather than whole-community FMT.

A high-resolution strain-tracking framework was developed and applied to analyze over 2,000 metagenomes from diverse disease cohorts and healthy controls.

• The framework enabled strain-level resolution beyond standard species-level metagenomic analysis.
• The dataset included more than 2,000 metagenomes.
• Cohorts included both diverse disease populations and healthy controls.
• The framework was used to identify phylogenetically distinct strains and track their engraftment dynamics post-FMT.